Physician profile
Mark W Lastarza
NPI 1831165448
$2,351.67
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $243 · 2021: $536 · 2022: $506 · 2023: $422 · 2024: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $570.89 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $250.83 | 2020-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $246.57 | 2020-2024 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $189.68 | 2021-2024 | |
| Pfizer INC. | $137.84 | 2019-2024 | |
| Amgen INC. | $126.83 | 2021-2024 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $123.62 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Abbott Laboratories | $119.01 | 2021-2023 | Freestyle Libre 3 |
| Abbvie INC. | $86.09 | 2021-2022 | |
| Astellas Pharma US INC | $78.63 | 2023-2024 | Veozah |
| Amarin Pharma, INC. | $72.28 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.30 | 2020-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $54.38 | 2020-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.26 | 2019-2022 | |
| Exact Sciences Corporation | $42.73 | 2023-2024 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $23.10 | 2022 | |
| Renalytix Ai, INC. | $22.21 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Axonics, INC. | $22.08 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.66 | 2023 | Gvoke Hypopen |
| Biogen, INC. | $18.56 | 2021 | |
| Medtronic, INC. | $16.12 | 2024 | Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $13.00 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lastarza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.